The Latin America, Middle East and Africa Hemoglobinopathies Market should witness market growth of 8.6% CAGR during the forecast period (2022-2028).
To measure the level of different types of hemoglobin in the blood, hemoglobin electrophoresis is used. Hb electrophoresis, sickle cell - electrophoresis, and hemoglobinopathy - electrophoresis are some of the alternative names used for this test. A notable level of HbA and HbA2 is present in healthy adults, but some individuals may also have a small amount of HbF in their blood. This is the primary type of hemoglobin in the body of an unborn child.
Some illnesses are also connected with the amount of HbF in the blood (only if the level of HbF is more than 2% of the total hemoglobin). The abnormal form of hemoglobin associated with sickle cell anemia is HbS, and the other unusual hemoglobin form HbC is associated with hemolytic anemia. Its symptoms are quite mild when compared to sickle cell anemia. Hemoglobinopathies are genetic disorders. They are taken on as single-gene illnesses, causing problems like sickle cell disease.
Genetic and blood testing, hemoglobin electrophoresis, HbA2 quantitative analysis by ion exchange column chromatography, pre-implantation genetic diagnosis, and alkaline & acid gel electrophoresis are the most widely used tests for the identification of thalassemia and other hemoglobinopathy diseases. Hemoglobinopathies are considered to be one of the most widely diagnosed inherited diseases. Also, due to immigration, it has become common in other parts of the world.
In Middle Eastern Arab countries, the Sickle hemoglobin (HbS) gene occurs at a different frequency, with unique distribution patterns and a picture of overall blood genetic disorders in the region. The origin of the gene is disputed, but studies have shown, using beta-globin gene haplotypes, that there were various origins for Sickle hemoglobin. The sickle hemoglobin gene is common and displays polymorphism in some regions, while the vice versa is also true in other regions.
The Brazil market dominated the LAMEA Hemoglobinopathies Market by Country in 2021; thereby, achieving a market value of $105.4 Million by 2028. The Argentina market is showcasing a CAGR of 9.2% during (2022-2028). Additionally, The UAE market would register a CAGR of 8.3% during (2022-2028).
Based on Type, the market is segmented into Thalassemia, Sickle Cell Disease and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacy, Hospital Pharmacy and Online Providers. Based on Therapy, the market is segmented into Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck & Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.
To measure the level of different types of hemoglobin in the blood, hemoglobin electrophoresis is used. Hb electrophoresis, sickle cell - electrophoresis, and hemoglobinopathy - electrophoresis are some of the alternative names used for this test. A notable level of HbA and HbA2 is present in healthy adults, but some individuals may also have a small amount of HbF in their blood. This is the primary type of hemoglobin in the body of an unborn child.
Some illnesses are also connected with the amount of HbF in the blood (only if the level of HbF is more than 2% of the total hemoglobin). The abnormal form of hemoglobin associated with sickle cell anemia is HbS, and the other unusual hemoglobin form HbC is associated with hemolytic anemia. Its symptoms are quite mild when compared to sickle cell anemia. Hemoglobinopathies are genetic disorders. They are taken on as single-gene illnesses, causing problems like sickle cell disease.
Genetic and blood testing, hemoglobin electrophoresis, HbA2 quantitative analysis by ion exchange column chromatography, pre-implantation genetic diagnosis, and alkaline & acid gel electrophoresis are the most widely used tests for the identification of thalassemia and other hemoglobinopathy diseases. Hemoglobinopathies are considered to be one of the most widely diagnosed inherited diseases. Also, due to immigration, it has become common in other parts of the world.
In Middle Eastern Arab countries, the Sickle hemoglobin (HbS) gene occurs at a different frequency, with unique distribution patterns and a picture of overall blood genetic disorders in the region. The origin of the gene is disputed, but studies have shown, using beta-globin gene haplotypes, that there were various origins for Sickle hemoglobin. The sickle hemoglobin gene is common and displays polymorphism in some regions, while the vice versa is also true in other regions.
The Brazil market dominated the LAMEA Hemoglobinopathies Market by Country in 2021; thereby, achieving a market value of $105.4 Million by 2028. The Argentina market is showcasing a CAGR of 9.2% during (2022-2028). Additionally, The UAE market would register a CAGR of 8.3% during (2022-2028).
Based on Type, the market is segmented into Thalassemia, Sickle Cell Disease and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacy, Hospital Pharmacy and Online Providers. Based on Therapy, the market is segmented into Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck & Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.
Scope of the Study
By Type
- Thalassemia
- Sickle Cell Disease
- Others
By Distribution Channel
- Drug Stores & Retail Pharmacy
- Hospital Pharmacy
- Online Providers
By Therapy
- Monoclonal Antibody Medication
- Hydroxyurea
- ACE Inhibitors
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Sanofi S.A.
- Danaher Corporation
- Pfizer, Inc. (Global Blood Therapeutics, Inc.)
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Alnylam Pharmaceuticals, Inc.
- Emmaus Life Sciences, Inc.
- Biogen, Inc.
- Canthera Discovery Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Hemoglobinopathies Market by Type
Chapter 4. LAMEA Hemoglobinopathies Market by Distribution Channel
Chapter 5. LAMEA Hemoglobinopathies Market by Therapy
Chapter 6. LAMEA Hemoglobinopathies Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Sanofi S.A.
- Danaher Corporation
- Pfizer, Inc. (Global Blood Therapeutics, Inc.)
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Alnylam Pharmaceuticals, Inc.
- Emmaus Life Sciences, Inc.
- Biogen, Inc.
- Canthera Discovery Ltd.
Methodology
LOADING...
